Navigation Links
NYU Langone researchers identify a signaling pathway as possible target for cancer treatment
Date:8/15/2011

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

"We have known for a long time that blood vessels branch to give rise to new ones and that in some places of our bodies this branching occurs with a reproducible pattern. However, the mechanisms that ensure that new vessels sprout at specific locations had not been uncovered until now," said Jess Torres-Vzquez, PhD, assistant professor of Developmental Genetics at the Skirball Institute of Biomolecular Medicine at NYU School of Medicine. "Our study illuminates the genetic basis behind the reproducible pattern of the vasculature and suggests ways in which the formation of new blood vessels could be modulated to treat certain cancers in the future."

Using the zebrafish embryo as a model system, researchers identified that Semaphorin-PlexinD1 signaling limits the formation of new blood vessels. This signaling pathway works by ensuring that blood vessels make the proper levels of soluble Flt1. Soluble Flt1 is an inhibitor of the Vascular Endothelial Growth Factor (VEGF) pathway, which promotes the growth of new blood vessels.

These findings have broad implications for human health, since changes in the level of soluble Flt1 are associated with cancer, vascular birth defects and pregnancy-related hypertension (preeclampsia).

According to researchers, the Semaphorin-PlexinD1 signaling pathway shows significant promise as a future therapeutic target for cancer treatment to slow the progression of diseases by controlling the blood vessel growth.


'/>"/>

Contact: Christopher Rucas
christopher.rucas@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

0

GOOD

Page: 1

Related biology news :

1. NYU Langone Medical Centers tip sheet to the 2011 Alzheimers Association International Conference
2. NYU Langone experts present advances at American Association of Neurological Surgeons Meeting
3. NYU Langone Medical Center receives $5.4 million NYSTEM grant for stem cell research
4. NYU Langone Medical Center awarded NIH grants totaling $1,560,000
5. NYU Langone Medical Center researchers find micro RNA plays a key role in melanoma metastasis
6. Toronto researchers first to discover new genetic clue in the development of rheumatoid arthritis
7. Researchers decode workings of mysterious, but critical TB drug
8. Researchers fight cholera with computer forecasting
9. Vanderbilt researchers, international team, uncover genes linked to multiple sclerosis
10. Narcissism may benefit the young, researchers report; but older adults? Not so much
11. York U researchers zero in on protein that may help treat obesity, diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 MedNet Solutions , ... study management systems, is pleased to announce its participation ... June 23-27 in Boston .  This ... recognized leader in cloud-based eClinical solutions, has exhibited at ... showcasing iMedNet™ EDC , MedNet,s latest, ...
(Date:6/19/2013)... the most perfectly spherical large objects in nature may ... new study. It appears in ACS, journal Langmuir ... Julyan Cartwright, Antonio G. Checa and Marthe Rousseau point ... have perhaps the most perfectly spherical, or ball-like, shape ... without a microscope. Pearls develop as nacre (mother of ...
(Date:6/19/2013)... 2012, the European Medicines Agency (EMA) approved the ... ever gene therapy for clinical use in the ... developed AAV-LPL S447X for the treatment of a ... (LPLD) which affects approximately one or two out ... life-threatening inflammations of the pancreas. Afflicted individuals carry ...
Breaking Biology News(10 mins):MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2No danger of cancer through gene therapy virus 2
... Cones, holes and temporary traffic lights the scourge of ... together to reduce the misery of motorists caused by ... under the tarmac. They,ll reveal how new technology will ... digging. A sector-wide seminar at The University of ...
... New Orleans, LA Research led by David Worthylake, PhD, ... Sciences Center New Orleans, may help lay the groundwork for ... cancer. The research will be published in the May 29, ... During the transition from a localized tumor to metastatic ...
... NOT trying to assert their dominance over their canine ... at the University of Bristol,s Department of Clinical Veterinary ... Applications and Research . The researchers spent six ... rehoming centre, and reanalysing data from studies of feral ...
Cached Biology News:Reducing the roadworks 2Reducing the roadworks 3LSUHSC research describes function of key protein in cancer spread 2Using 'dominance' to explain dog behavior is old hat 2
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... BioConvergence team members Curtis Strother ... 2013’s BioLogistics Summit in San Francisco earlier this ... Chain IQ and IQPC, addressed the increasingly complex ... part, attributed to current trends of globalization, outsourcing, ... trends is an increase in movement, which is ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased ... measurement of sulfur in ultra-low sulfur diesel (ULSD) using ... EDXRF analyzer . The analysis detailed in Rigaku Application ... This International Standard specifies an energy dispersive X-ray ... content in automotive gasoline. , Regulations around the world ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Encorium Group, Inc. (Nasdaq: ENCO ), a full service ... for many of the world,s leading pharmaceutical and biotechnology companies, today ... Nasdaq stating that since it had not, as of the date ... June 30, 2009, it was then no longer in compliance with ...
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , , , , ... PPHM ) today announced that it will release its financial results for ... 7:00 a.m. EDT and will host a conference call and webcast to ... , Peregrine,s senior management will discuss financial results for ...
Cached Biology Technology:Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 2Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 3Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
... BAS-2500 is ideal for ... Biology (1D electrophoresis, 2D ... Macroarrays); Pharmacokinetics & Toxicology ... layer chromatography); Physical and ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
Biology Products: